A systematic review of population based epidemiological studies in Myasthenia Gravis

BMC Neurology

Volumn 10, Issue , 2010, Pages

  Carr, Aisling S ^a   Cardwell, Chris R ^b   McCarron, Peter O ^b   McConville, John ^a,c  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c ULSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY;

AGE; ARTICLE; ENVIRONMENTAL FACTOR; HEALTH SURVEY; HUMAN; INCIDENCE; MORTALITY; MYASTHENIA GRAVIS; POPULATION RESEARCH; PREVALENCE; PUBLICATION; SEX DIFFERENCE; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREND STUDY; META ANALYSIS; REVIEW;

HUMANS; INCIDENCE; MYASTHENIA GRAVIS; PREVALENCE;

EID: 77953633370     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-10-46     Document Type: Article

References (64)

1. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009, 8(5):475-90. 10.1016/S1474-4422(09)70063-8, 2730933, 19375665.
2. Lindstrom JM, Seybold ME, Lennon VA, et al. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976, 26(11):1054-9.
3. Hoch WJ, McConville J, Helms S, et al. Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7(3):365-368. 10.1038/85520, 11231638.
4. Kurtzke JF. Epidemiology of myasthenia gravis. Advances in Neurology 1978, 19:545-566.
5. Phillips LH, Torner JC. Epidemiologic evidence for changing natural history of myasthenia gravis. Neurology 1996, 47:1233-1238.
6. Osserman KE, Genkins G. Studies in myasthenia gravis: review of twenty years experience in over 120 patients. Mt Sinai J Med 1971, 38(6):497-537.
7. Age standardisation of rates: a new WHO standard (2000). Appendix D. [online]. Accessed 2nd September 2008., http://www.who.int/whosis/statistics/discussion_papers/pdf/paper31.pdf
8. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-60. 10.1136/bmj.327.7414.557, 192859, 12958120.
9. Mathisen S. Epidemiology of myasthenia gravis in Norway. Acta Neurol Scand 1984, (70):274-284.
10. Kurland LT. Descriptive epidemiology if selected neurologic and myopathic disorders with particular reference to a survey in Rochester Minnesota. J Chronic Disorders 1958, 8(4):378.
11. Garland H, Clark ANG. Myasthenia gravis, a personal study of 60 cases. BMJ 1956, 1:1259-1262. 10.1136/bmj.1.4978.1259, 1979663, 13316124.
12. Alter M, Rhett-Talbert O, Kurland LT. Myasthenia gravis in a southern community. Arch Neurol 1960, 3:65-69.
13. Pennington GW, Wilson A. Incidence of myasthenia gravis in the Merseyside conurbation. Myasthenia Gravis. Proceedings of the second international symposium 1961, 337-45. Springfield IL: Charles C Thomas, Veits HR.
14. Gudmundsson KR. The prevalence of some neurological diseases in Iceland. Acta Neurol Scand 1968, (44):55-69.
15. Oosterhuis Epidemiologie dei myasthenie in Amsterdam. Neurologie Deutsche Jesells 1977, 103-108. Oosterhuis.
16. Okinaka S, Reese HH, Katsuki S, et al. The prevalence of multiple sclerosis and other neurological diseases in Japan. 1966, 47(Suppl 19):68-76.
17. Hokkanen E. Epidemiology of myasthenia gravis in Finland. J Neurol Sci 1969, (9):463-478. 10.1016/0022-510X(69)90090-2, 5367040.
18. Deffeminis Rospide HA, Petra de Mirabel M, Piazza de Silva N, et al. Estudio epidemiologico de la miastenia en el Uruguay. Acta Neurol Latinoamer 1975, (21):53-65.
19. Araki S, Uchino M, Yoshida O. Epidemiologic study of multiple sclerosis, myasthenia gravis and polymyositis in the city of Kumamoto, Japan. Clin Neurol 1983, 23:838-841.
20. Phillips LH, Torner JC, Anderson MS, Cox GM. The epidemiology of myasthenia gravis in central and western Virginia. Neurology 1992, 42:1888-1894.
21. Kvirkveliia NB. Clinico-epidemiologic aspects of myasthenia in the Georgian SSR. Zh Nevropatol Psikhiatr Im S S Korsakova 1986, 86(3):327-30.
22. Kondo K, Takasu T, Ahmed A. Neurological diseases in Karachi, Pakistan - elevated occurrence of subacute sclerosing panencephalitis. Neuroepidemiology 1988, 7:66-80. 10.1159/000110138, 3374729.
23. Giagheddu M, Puggioni G, Sanna G, et al. Epidemiological study of myasthenia gravis in Sardinia Italy (1958-1986). Acta Neurol Scand 1989, 79:326-333. 10.1111/j.1600-0404.1989.tb03793.x, 2728857.
24. Radhakrishnan K, Thacker AK, Maloo JC, Gerryo SE, Mousa ME. Descriptive epidemiology of some rare neurological diseases in Benghazi, Libya. Neuroepidemiology 1988, 7(3):159-64. 10.1159/000110150, 3405368.
25. D'Alessamdro R, Granieri E, Benassi G, et al. Comparative study on the prevalence of myasthenia gravis in the provinces of Bologna and Ferrera Italy. Acta Neurol Scand 1991, 83(2):83-88. 10.1111/j.1600-0404.1991.tb04654.x, 2017902.
26. Yu YL, Hawkins BR, Ip MS, Wong V, Woo E. Myasthenia gravis in Hong Kong Chinese: Epidemiology and adult disease. Acta Neurol Scand 1992, 86(2):113-119. 10.1111/j.1600-0404.1992.tb05050.x, 1414218.
27. Sorensen TT, Holm EB. Myasthenia gravis in the county of Viborg, Denmark. Eur Neurol 1989, (29):177-179.
28. Somnier FE, Keiding N, Paulson OB. Epidemiology of myasthenia gravis in Denmark: A longitudinal and comprehensive population survey. Archives of Neurology 1991, 48(7):733-739.
29. Christensen PB, Jensen TS, Tsiropoulos I, et al. Mortality and survival in myasthenia gravis: a Danish population based study. JNNP 1998, 64(1):78-83.
30. Ferrari G, Lovaste MG. Epidemiology of myasthenia gravis in the province of Trento (northern Italy). Neuroepidemiology 1992, 11(3):135-42. 10.1159/000110923, 1407249.
31. Christensen PB, Jensen TS, Tsiropoulos I, et al. Incidence and prevalence of myasthenia gravis in western Denmark:1975-1989. Neurology 1993, 43(9):1779-83.
32. Cisernos AD, Luis RS, Leon R, Carrera PL. Some epidemiological aspects of myasthenia gravis in Cuba. Revista de Neurologia 1996, 24(128):435-9.
33. Krivopusk ME. Clinico-epidemiological aspects of hereditary neuromuscular diseases in the Krasnodar territory. Zhurnal Nevropatologii I Psikhiatrii Imeni SS Korsakova 1991, 91(9):3-5.
34. Lavrnic D, Jarebinski M, Rakocevic-Stojanovic V, et al. Epidemiological and clinical characteristics of myasthenia gravis in Belgrade, Yugoslavia (1983-1992). Acta Neurologica Scandanavica 1999, 100(3):168-74.
35. Aiello I, Pastorino M, Sotgui S, et al. Epidemiology of myasthenia gravis in northwestern Sardinia. Neuroepidemiology 1997, 16(4):199-206. 10.1159/000109688, 9267837.
36. Guidetti D, Sabadini R, Bondavalli M, et al. Epidemiological study of myasthenia gravis in the province of Reggio Emilia, Italy. European Journal of Epidemiology 1998, 14(4):381-7. 10.1023/A:1007449221638, 9690757.
37. Study group on clinical and epidemiological problems in Neurology Incidence of myasthenia gravis in the Emilia-Romagna region: a prospective multi-centre study. Neurology 1998, 51(1):255-8. Study group on clinical and epidemiological problems in Neurology.
38. Kyriallis K, Hristova A, Middleton I. What is the real epidemiology of myasthenia gravis?. Neurology 1995, (suppl 4):A351.
39. MacDonald BK, Sander WAS, Shorvom SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000, 123:685-76.
40. Holtsema H, Mourik J, Rico RE, et al. Myasthenia gravis on the Dutch Antilles: an epidemiological study. Clinical Neurology and Neurosurgery 2000, 102(4):195-198. 10.1016/S0303-8467(00)00103-7, 11154803.
41. Villagra-Cocco A, Villagra-Cocco P. Prevalence of myasthenia gravis on the island of La Palma. Revista de Neurologia 1997, 25(148):2068-9.
42. Zivadinov R, Jurjevic A, Willhein K, Cazzato G, Zorzon M. Incidence and prevalence of myasthenia gravis in the county of the coast and Gorski Kotar, Croatia. Neuroepidemiology 1998, 17(5):265-72. 10.1159/000026179, 9705586.
43. Robertson NP, Deans J, Compston DA. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry 1998, 65(4):492-496. 10.1136/jnnp.65.4.492, 2170309, 9771771.
44. El-Tallawy HN, Khedr EM, Qayed MH, Helliwell TR, Kamel NF. Epidemiological study of neuromuscular disorders in Assuit, Egypt. Neuroepidemiology 2005, 25(4):205-211. 10.1159/000088674, 16210862.
45. Oopik M, Kaasik AE, Jakobson J. A population based epidemiological study of myasthenia gravis in Estonia. JNNP 2003, 74(12):1638-43.
46. Kalb B, Matell G, Pirskanen R, Lambe M. Epidemiology of myasthenia gravis: a population based epidemiological study in Stockholm, Sweden. Neuroepidemiology 2002, 21(5):221-5. 10.1159/000065639, 12207149.
47. Matuja WBP, Aris EA, Gabone J, Mgaya EM. Incidence and characteristics of myasthenia gravis in Dar Es Salaam, Tanzania. East African Medical Journal 2001, 78(9):473-476.
48. Sanchez JL, Uribe CS, Franco AF, Jimeniz ME, Arcos-Burgos OM, Palacio LG. Prevalence of myasthenia gravis in Antioquia, Colombia. Revista de Neurologia 2002, 34(11):1010-2.
49. Wirtz PW, Nijnuis MG, Sotodeh M, et al. The epidemiology of myasthenia gravis, Lambert Eaton myasthenic syndrome and their associated tumours in the northern part of Southern Holland. Journal of Neurology 2003, 250(6):698-701. 10.1007/s00415-003-1063-7, 12796832.
50. Matssuda M, Dohi-Iijima N, Nakamura A. Increase in incidence of elderly onset patients with myasthenia gravis in Nagano Prefecture, Japan. Internal Medicine 2005, 44(6):572-7. 10.2169/internalmedicine.44.572, 16020882.
51. Aragones JM, Bolibar I, Bonfill X, et al. Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 2003, 60(6):1024-6.
52. Eaton WW, Rose NR, Kalaydjian A, Pederson MG, Mortensen PB. Epidemiology of autoimmune diseases in Denmark. Journal of Autoimmunity 2007, 29(1):1-9. 10.1016/j.jaut.2007.05.002, 2717015, 17582741.
53. Kotov SV, Neretin VI, Agafonov BV, Sidorova OP. Population based study of myasthenia in Moscow region. Zhurnal Nevrologii I Psikhiatrii Imeni SS Korsakova 2006, 106(5):52-5.
54. Niks EH, Kuks JB, Verschuuren JJ, et al. Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands. JNNP 2007, 78(4):417-8.
55. Somnier FE. Increasing incidence of late onset anti-AChR antibody-seropositive myasthenia gravis. Neurology 2005, 65:928-930. 10.1212/01.wnl.0000176067.32186.a3, 16186537.
56. Oger J, Wang L, Aziz T, et al. The age of onset and the incidence of myasthenia gravis are increasing in British Columbia (Canada). Journal of the Neurological Sciences 2002, 199(suppl 1):S45-S45.
57. Poulas K, Tsibri E, Kokla A, et al. Epidemiology of seropositive myasthenia gravis in Greece. JNNP 2001, 71(3):352-6.
58. Vincent A, Clover L, Buckley C, Grimley-Evans J, Rothwell PM. Evidence of underdiagnosis of myasthenia gravis in older people. JNNP 2003, 74(8):1105-8.
59. Farrugia ME. A limited epidemiological study of seropositive myasthenia gravis in Tayside. Scottish Medical Journal 2002, 46(7):132-135.
60. Heldal AT, Owe JF, Gilhus NE, et al. Acetylcholine receptor antibodies in Norwegian myasthenia gravis patients. European Journal of Neurology 2008, 15(suppl 3):154.
61. Bateman KJ, Schinkel M, Little F, Leidenberg L, Vincent A, Heckmann JM. Incidence of seropositive myasthenia gravis in Cape Town and South Africa. South African Medical Journal 2007, 97(10):959-62.
62. Tsiamalos P, Kordas G, Kokla A, et al. Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece. European Journal of Neurology 16(8):925-930. 10.1111/j.1468-1331.2009.02624.x, 19374661.
63. Vincent A, Leite MI, Farrugia ME, et al. Myasthenia Gravis seronegative for acetylcholine receptor antibodies. Ann N Y Acad Sci 2008, 1132:84-92. 10.1196/annals.1405.020, 18567857.
64. Leite MI, Jacob S, Veigas S, et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008, 131(7):1940-1952. 10.1093/brain/awn092, 2442426, 18515870.